For important risk and disclaimer information, Click here.
 |
Rashidah Billups | Managing Director
|
 |
rbillups@castleplacement.com |
 |
(917) 553-6532
|
OVERVIEW
Allure Global Inc., a regulatory-backed functional wellness platform positioned within the emerging ‘Wellness 2.0’ landscape, is raising $25 million to transition from infrastructure build-out to structured commercialization across national retail, direct-to-consumer, and pharmaceutical channels.
Outcome-driven, science-forward evolution of the global health economy.
Rather than pursuing speculative scale, Allure Global has deliberately built institutional-grade infrastructure prior to commercialization.
Milestones
Strategic media integration with DOE Media and Brown & Dutch PR
Distribution engagement with KeHE and Accesso Brazil
Investment Opportunity
Differentiated entry point into the rapidly maturing functional cannabinoid category, combining regulatory defensibility, premium formulation science, and multi-channel scalability.
Financial Projections
Allure Global Inc. is a premium functional wellness platform positioned at the intersection of clinical cannabinoid science and scalable consumer packaged goods execution. The Company is raising $25 million in exchange for 25% equity, implying a $100 million post-money valuation.
Why Now?
The cannabinoid category is entering its second institutional phase. The initial wave of fragmented entrants created awareness but compressed pricing.
The next phase favors compliant, capitalized operators capable of delivering:
Market Positioning / Competitive Advantage
Unlike many CBD brands that compete solely on isolate concentration or price, Allure competes on formulation science, regulatory integrity, and brand architecture.
Competitive differentiation includes:
In a fragmented marketplace, differentiation is structural – not cosmetic.
MARKET OPPORTUNITY
Global CBD market estimated at $9.14B in 2024, projected to exceed $22B by 2030 at ~15.8% CAGR
COMMERCIALIZED PRODUCT PORTFOLIO
Existing Symptom-Based Solutions
The core competitive advantage of Allure Global resides in its existing product architecture, which moves consumer conversation away from generic labels and toward functional, outcome-oriented stacks.
Each product is manufactured in state-of-the-art facilities with elite certifications, including cGMP, ISO-17025, and non-GMO
STRATEGIC ROADMAP
The implementation of the expansion strategy follows a meticulous quarterly timeline for 2026, focusing on “winning the shelf” in national retail.
MANAGEMENT TEAM
Alexander Sandro Costa
Founder, President & CEO
30+ years in regulated sectors, prior CEO roles in energy and clean tech. York University, Math for Commerce and Economics
Claire Morris
Co-Founder, COO
25+ years scaling organizations with $70M+ revenues. Expert in tactical execution, sales/service integration, and strategic growth. Bachelor of Business, Ryerson University
Justin Costa
Marketing Specialist
Skilled in omni-channel digital marketing, content creation, and CRM optimization. Bachelor of Business Economics, York University
SPECIFIC RISKS
→ Regulatory Risk
US federal CBD regulatory uncertainty and potential FDA action
→ Execution Risk
Successful expansion from initial retail penetration to broader national distribution depends on achieving consistent shelf velocity, effective trade spend deployment, and operational coordination across retail partners. Failure to meet performance thresholds could slow door expansion or require incremental capital to support sell-through
→ Supply Chain Risk
Ensuring inventory and production capacity match rapid growth
→ Financial Risk
High marketing burn and customer acquisition cost inflation
→ Retail Concentration & Slotting Risk
Commercialization strategy relies on successful sell-in and sustained velocity within national retail channels. Failure to meet retailer performance thresholds or offset slotting and promotional costs could delay expansion, reduce shelf space, or require incremental capital.
→ Category Perception & Compliance Risk
Cannabinoid-based products remain subject to evolving consumer perception, retailer policy changes, and regulatory scrutiny
Private securities are speculative, illiquid, and carry risk including total loss of investment
